# AstraZeneca Farxiga approved in the US by FDA

- Link: https://www.directorstalkinterviews.com/astrazeneca-farxiga-approved-in-the-us-by-fda/412795800
- Published: 2019-10-21T07:15:35+01:00
- Author: Amilia Stone

Ast**raZeneca** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
announced that the US Food and Drug Administration has approved _Farxiga_ (dapagliflozin)
to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-
2 diabetes  and established cardiovascular disease or multiple cardiovascular risk
factors.

The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial(
CVOT), the largest sodium-glucose cotransporter 2 (SGLT2) inhibitor CVOT conducted
to date to evaluate T2D patients with multiple CV risk factors or established CV
disease.

> **Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said**:“
> _Farxiga_ is the first SGLT2 inhibitor approved in the US to reduce the risk of
> hospitalisation for heart failure in type-2 diabetes patients with established
> cardiovascular disease or multiple cardiovascular risk factors. This is promising
> news for the 30 million people living with type-2 diabetes in the US, as heart
> failure is one of the earliest cardiovascular complications for them, before heart
> attack or stroke. _Farxiga_ now offers the opportunity for physicians to act sooner
> and reduce the risk of hospitalisation for heart failure.”

> **Dr. Stephen Wiviott of Brigham and Women’s Hospital and Harvard Medical School,
> Boston, US and a Senior Investigator with the TIMI study group and co-principal
> investigator of the trial, said**: “DECLARE-TIMI 58 is a landmark trial, offering
> compelling evidence that dapagliflozin can reduce the risk of heart failure in
> patients living with type-2 diabetes with multiple risk factors for or established
> cardiovascular disease. These data could help change the way we approach diabetes
> management – going beyond a singular focus on glucose control to help address 
> the risk of heart failure in a diverse population of patients.”

Today’s US FDA approval follows the update to the marketing authorisation in the
EU in August 2019. _Farxiga_ is also under regulatory review in China with a decision
anticipated in the first half of 2020.

The US FDA has granted Fast Track designation for _Farxiga_ to reduce the risk of
CV death, or the worsening of heart failure in adults with heart failure with reduced
ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) based on the Phase
III DAPA-HF and DELIVER trials, and Fast Track designation to delay the progression
of renal failure and prevent CV and renal death in patients with chronic kidney 
disease (CKD) based on the Phase III DAPA-CKD trial.

**About _Farxiga_**

_Farxiga_ is a first-in-class, oral once-daily SGLT2 inhibitor indicated as both
monotherapy and as part of combination therapy to improve glycaemic control, with
the additional benefits of weight loss and blood pressure reduction, as an adjunct
to diet and exercise in adults with T2D. _Farxiga_ has a robust programme of clinical
trials that includes more than 35 completed and ongoing Phase IIb/III trials in 
more than 35,000 patients, as well as more than 2.5 million patient-years’ experience.

**About DECLARE-TIMI 58**

DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58 is the largest CV
outcomes trial conducted for a selective inhibitor of SGLT2 to date in a broad patient
population. It is an AstraZeneca-sponsored, Phase III, randomised, double-blind,
placebo-controlled, multicentre trial designed to evaluate the effect of _Farxiga_
compared with placebo on CV outcomes in adults with T2D at risk of CV events, including
patients with multiple CV risk factors or established CV disease and also assessed
key renal secondary endpoints. The trial included more than 17,000 patients across
882 sites in 33 countries and was independently run in collaboration with academic
investigators from the TIMI study group (Boston, US) and the Hadassah Hebrew University
Medical Center (Jerusalem, Israel).

DECLARE-TIMI 58 showed that _Farxiga_ significantly reduced the risk of the primary
composite endpoint of hHF or CV death versus placebo by 17% (4.9% vs. 5.8%; HR 0.83[
95% CI 0.73-0.95], p=0.005). This finding was driven by a significant 27% reduction
in the risk of hHF (2.5% vs. 3.3%; HR 0.73 [95% CI 0.61, 0.88]). The treatment benefit
was consistent across patient subgroups. The Phase III DECLARE-TIMI 58 trial confirmed
the well-established safety profile of _Farxiga_.

The full results of the DECLARE-TIMI 58 trial were published in The New England 
Journal of Medicine in January 2019.

**About AstraZeneca in Cardiovascular, Renal and Metabolism**

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs
and improve outcomes by slowing disease progression, reducing risks and tackling
comorbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal and Metabolism (CVRM), and Respiratory. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide. For more
information, please visit [astrazeneca](http://www.astrazeneca.com/)[.](http://www.astrazeneca.com/)
[com](http://www.astrazeneca.com/) and follow us on Twitter @[AstraZeneca](https://clicktime.symantec.com/37Bg16U1oCzfevsztvEsc5x6H2?u=https%3A%2F%2Ftwitter.com%2FAstraZeneca).

Share on:
